Fig. 6. Ryanodine receptor-2 (RyR2; 560 kDa) phosphorylation given as ratio between p-RyR2 to total RyR2 for combo treatments (A ) and representative immunoblots (B ). CTL, time-matched aerobic control; IR, ischemia–reperfusion alone; SEVO/PROP+IR, periischemic sevoflurane (2 vol.-%) plus propofol (10 μM) treatment; REMI/PROP+IR, periischemic remifentanil (3 nM) plus propofol (10 μM) treatment; REMI/SEVO+IR, periischemic remifentanil (3 nM) plus sevoflurane (2 vol.-%) treatment. *P < 0.05 compared with IR. §P < 0.05 compared with CTL. Data are mean ± SD.

Fig. 6. Ryanodine receptor-2 (RyR2; 560 kDa) phosphorylation given as ratio between p-RyR2 to total RyR2 for combo treatments (A ) and representative immunoblots (B ). CTL, time-matched aerobic control; IR, ischemia–reperfusion alone; SEVO/PROP+IR, periischemic sevoflurane (2 vol.-%) plus propofol (10 μM) treatment; REMI/PROP+IR, periischemic remifentanil (3 nM) plus propofol (10 μM) treatment; REMI/SEVO+IR, periischemic remifentanil (3 nM) plus sevoflurane (2 vol.-%) treatment. *P < 0.05 compared with IR. §P < 0.05 compared with CTL. Data are mean ± SD.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal